Genmab Gross Profit 2019-2022 | GMAB
Genmab annual/quarterly gross profit history and growth rate from 2019 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Genmab gross profit for the quarter ending March 31, 2022 was $0.320B, a 24.69% increase year-over-year.
- Genmab gross profit for the twelve months ending March 31, 2022 was $1.413B, a 15.58% decline year-over-year.
- Genmab annual gross profit for 2021 was $1.349B, a 12.88% decline from 2020.
- Genmab annual gross profit for 2020 was $1.549B, a 92.58% increase from 2019.
- Genmab annual gross profit for 2019 was $0.804B, a 67.86% increase from 2018.
Genmab Annual Gross Profit
(Millions of US $) |
| 2021 |
$1,349 |
| 2020 |
$1,549 |
| 2019 |
$804 |
| 2018 |
$479 |
Genmab Quarterly Gross Profit
(Millions of US $) |
| 2022-03-31 |
$320 |
| 2021-12-31 |
$407 |
| 2021-09-30 |
$366 |
| 2021-06-30 |
$320 |
| 2021-03-31 |
$256 |
| 2020-12-31 |
$341 |
| 2020-09-30 |
$271 |
| 2020-06-30 |
$805 |
| 2020-03-31 |
$132 |
| 2019-12-31 |
$443 |
| 2019-09-30 |
$155 |
| 2019-06-30 |
$117 |
| 2019-03-31 |
$90 |
| 2018-12-31 |
$196 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$20.430B |
$1.349B |
|
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
|
